ArticleBlood2026

Diefenbach CS, Jegede O, Wang V, et al. A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma. Blood. 2026;147(18):2041-2052.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.